Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.

van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, Fajgenbaum DC. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022 08 23; 6(16):4773-4781.

View in: PubMed

collapse authors with profiles